OS Therapies, Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of ...
Tessl raises $125m to transform how software is created in the AI era Tessl sets out to reimagine software development for the AI era by defining and enabling 'AI Native Software Development'Founded ...